Author

A. Inga

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:protein folding & dynamics· 2 Assay:proteomics· 2 Organism:yeast· 2 Approach:biophysical modeling· 1 Research Focus:chromatin & epigenetic regulation· 1

Frequent Co-Authors

A. Karlen· 2 shared C. Spinnler· 2 shared E. Hedstrom· 2 shared E. R. Dickinson· 2 shared G. Selivanova· 2 shared J. Zawacka-Pankau· 2 shared K. Fawkner· 2 shared L.-G. Larsson· 2 shared

Activity by Year

2018-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

A. Karlen

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

The presence of a G4 prone sequence upstream of a minimal promoter increases transcriptional activity in the yeast S. cerevisiae

L. Kratochvilova, M. Vojsovic, N. Valkova, L. Sislerova, Z. El Rashed, A. Inga, P. Monti, V. Brazda

The paper investigates how G4 prone sequences upstream of a minimal promoter in yeast affect transcriptional activity, finding that they increase basal promoter activity and enhance P53 family protein-dependent expression.

bioRxiv · Jun 23, 2023 · PreprintCancer Biology

Structural Basis of Mutation-Dependent p53 Tetramerization Deficiency

M. Rigoli, G. Spagnolli, G. Lorengo, P. Monti, R. Potestio, E. Biasini, A. Inga

This study investigates how mutations in p53's tetramerization domain affect its structure and function using simulations and yeast assays, showing destabilizing effects and altered transactivation.

bioRxiv · May 13, 2022Cancer Biology

Novel allosteric mechanism of dual p53/MDM2 and p53/MDM4 inhibition by a small molecule

V. Grinkevich, V. Aparna, K. Fawkner, N. Issaeva, V. Andreotti, E. R. Dickinson, E. Hedstrom, C. Spinnler, A. Inga, L.-G. Larsson, A. Karlen, M. Wilhelm, P. Barran, A. Okorokov, G. Selivanova, J. E. Zawacka-Pankau

This paper identifies a novel allosteric mechanism by which RITA and PpIX inhibit p53/MDM2 and p53/MDM4 interactions, offering a new approach for p53 reactivation in cancer therapy.

bioRxiv · Dec 24, 2021Biochemistry

Novel allosteric mechanism of p53 activation by small molecules for targeted anticancer therapy

J. Zawacka-Pankau, V. V. Grinkevich, M. Burmakin, A. Vema, K. Fawkner, N. Issaeva, V. Andreotti, E. R. Dickinson, E. Hedstrom, C. Spinnler, A. Inga, L.-G. Larsson, A. Karlen, O. Tarasova, V. Poroikov, , G. Selivanova

This study identifies a novel allosteric mechanism by which small molecules activate p53 by blocking MDM2/MDMX binding, offering a new approach for anticancer therapy.

bioRxiv · Dec 7, 2018 · PreprintCancer Biology

Reactivation of TAp73 tumor suppressor by protoporphyrin IX, a metabolite of aminolevulinic acid, induces apoptosis in TP53-deficient cancer cells

A. Sznarkowska, A. Kostecka, A. Kawiak, P. Acedo, M. Lion, A. Inga, J. Zawacka-Pankau

The paper shows that protoporphyrin IX stabilizes and activates TAp73, inducing apoptosis in TP53-deficient cancer cells by disrupting interactions with MDM2/MDMX and inhibiting degradation by Itch.

bioRxiv · Aug 15, 2018Cancer Biology